ASND Ascendis Pharma A/S

NASDAQ
$225.60

Ascendis Pharma A/S (ASND) is expected to report earnings on November 16, 2026, before the market open. The consensus earnings estimate is $1.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.9% since its last earnings release on August 13, 2026.

Ascendis Pharma A/S Beat Expectations
Thursday, August 13, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 7:30 AM ET
Earnings Whisper
-
vs $1.13
Rev est $411.36M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $249.38

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies to address unmet medical needs.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.